Lyrica
Product Images NDC 42254-134

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Lyrica (NDC 42254-134). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rebel Distributors Corp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (Aac6c6a4 17a3 4643 Bc89 Db7259aca03a 01)

A mathematical formula for estimating creatinine clearance (CLCr) based on age in years, weight in kilograms, serum creatinine in mg/dL, and an adjustment factor for female patients. The formula shows the calculation steps clearly.*

FDA Label Image

Chemical Structure (Aac6c6a4 17a3 4643 Bc89 Db7259aca03a 02)

Chemical structure diagram of the active ingredient in Lyrica. The structure shows a molecule with an amino group and a carboxylic acid group, indicative of an amino acid derivative.*

FDA Label Image

Figure (Aac6c6a4 17a3 4643 Bc89 Db7259aca03a 03)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. The graph compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo, illustrating patient improvement rates at varied pain levels.*

FDA Label Image

Figure (Aac6c6a4 17a3 4643 Bc89 Db7259aca03a 04)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. Two lines represent Pregabalin 100 mg three times a day and placebo, comparing patient improvement percentages at various pain reduction levels.*

FDA Label Image

Figure (Aac6c6a4 17a3 4643 Bc89 Db7259aca03a 05)

A line graph showing the percent of patients improved plotted against percent improvement in pain from baseline. The graph compares Pregabalin at dosages of 75 mg, 150 mg, and 300 mg taken twice a day, as well as a placebo group. The percentage scale ranges from 0 to 100 on both axes, illustrating dose-dependent patient improvement trends.*

FDA Label Image

Figure (Aac6c6a4 17a3 4643 Bc89 Db7259aca03a 06)

A line graph showing the percent of patients improved against percent improvement in pain from baseline. It compares Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, illustrating their effectiveness in pain improvement.*

FDA Label Image

Figure (Aac6c6a4 17a3 4643 Bc89 Db7259aca03a 07)

A line graph showing the relationship between Percent Improvement in Pain from Baseline (x-axis) and Percent of Patients Improved (y-axis). It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and Placebo. The graph depicts greater improvement trends with higher dosages of Pregabalin relative to placebo.*

FDA Label Image

Figure (Aac6c6a4 17a3 4643 Bc89 Db7259aca03a 08)

A bar chart showing responder rates (%) from two studies labeled Study E1 and Study E3. The chart compares placebo and different dosages (50 mg/day, 300 mg/day, 600 mg/day) with responder rates increasing with dosage in both studies. Numerator sample sizes for each group are indicated beneath the bars. Some results are marked statistically significant versus placebo.*

FDA Label Image

Figure (Aac6c6a4 17a3 4643 Bc89 Db7259aca03a 09)

A line graph showing median percent reduction in seizure frequency from baseline on the Y-axis against dose in mg/day on the X-axis. The graph compares results from four studies labeled E1BD, E2TID, E3BD, and E3TID with data points at various doses, highlighting significant p-values showing seizure reduction at increasing doses up to 600 mg/day.*

FDA Label Image

Figure (Aac6c6a4 17a3 4643 Bc89 Db7259aca03a 10)

A line graph showing the percent improvement in pain from baseline among patients, comparing Pregabalin doses of 300 mg, 450 mg, and 600 mg daily against a placebo. The x-axis represents percent improvement in pain, and the y-axis represents the percent of patients improved, illustrating trends across different dosage groups.*

FDA Label Image

Figure (Aac6c6a4 17a3 4643 Bc89 Db7259aca03a 11)

A Kaplan-Meier survival curve comparing the estimated percentage of subjects without LTR over 180 days for Pregabalin versus Placebo. The vertical axis represents the estimated percentage of subjects without LTR, ranging from 0% to 100%. The horizontal axis shows the time in days from 0 to 180. Two lines display different trends: a solid line for Pregabalin and a dashed line for Placebo.*

FDA Label Image

Logo (Aac6c6a4 17a3 4643 Bc89 Db7259aca03a 12)

FDA Label Image

Logo (Aac6c6a4 17a3 4643 Bc89 Db7259aca03a 13)

FDA Label Image

Lyrica 225mg (Aac6c6a4 17a3 4643 Bc89 Db7259aca03a 14)

Lyrica 225mg capsules label showing 90 count. Each capsule contains 225mg Pregabalin. The white/light orange hard-gelatin capsule is printed with black ink "Pfizer" on the cap and "PGN 225" on the body. Distributed by Physician Partner, manufactured by Pfizer Pharmaceuticals LLC, Vega Baja, PR. Storage instructions specify controlled room temperature 15°-30°C (59°-86°F).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.